FOLFOX-4 vs. doxorubicin for hepatocellular carcinoma: Could a negative result be accepted as positive?

Journal of Hepatology

Volumn 61, Issue 1, 2014, Pages 164-165

  Liccioni, Alexandre ^a   Reig, Maria ^a   Bruix, Jordi ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; ANTINEOPLASTIC AGENT;

CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER SURGERY; CANCER SURVIVAL; CHINA; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HAZARD RATIO; HUMAN; KOREA; LIVER CELL CARCINOMA; LOCAL THERAPY; MULTICENTER STUDY (TOPIC); NOTE; OPEN STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TAIWAN; THAILAND; TREATMENT RESPONSE; CARCINOMA, HEPATOCELLULAR; FEMALE; LIVER NEOPLASMS; MALE; PALLIATIVE THERAPY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; PALLIATIVE CARE;

EID: 84902687174     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2014.03.024     Document Type: Note

References (10)

1. J.M. Llovet, S. Ricci, V. Mazzaferro, P. Hilgard, E. Gane, and J.F. Blanc et al. Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 2008 378 390
2. A.L. Cheng, Y.K. Kang, Z. Chen, C.J. Tsao, S. Qin, and J.S. Kim et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial Lancet Oncol 10 2009 25 34
3. S. Qin, Y. Bai, H.Y. Lim, S. Thongprasert, Y. Chao, and J. Fan et al. Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin vs. doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia J Clin Oncol 31 2013 3501 3508
4. A.L. Cheng, Y.K. Kang, D.Y. Lin, J.W. Park, M. Kudo, and S. Qin et al. Sunitinib vs. sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial J Clin Oncol 31 2013 4067 4075
5. Chinese Ministry of Health Diagnosis and treatment guideline of primary liver cancer ed. 2011 2011 Chinese Ministry of Health Beijing, China
6. Zhu A, Rosmorduc O, Evans J, Ross P, Santoro A, Carrilho FJ, et al. SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with hepatocellular carcinoma (HCC). Ann Oncol 2012;23(Suppl 9):ixe1-ixe30. Abstract LBA2.
7. Cainap C, Qin S, Huang W-T, Chung I-J, Pan H, Cheng Y, et al. Phase III trial of linifanib versus sorafenib in patients with advanced hepatocellular carcinoma (HCC). J Clin Oncol 2012;30(suppl 34). Abstract 249.
8. P.J. Johnson, S. Qin, J.W. Park, R.T. Poon, J.L. Raoul, and P.A. Philip et al. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study J Clin Oncol 31 2013 3517 3524
9. J.M. Llovet, T. Decaens, J.L. Raoul, E. Boucher, M. Kudo, and C. Chang et al. Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study J Clin Oncol 31 2013 3509 3516
10. Zhu A, Kudo M, Assenat E, Cattan S, Kang Y-K, Lin H-Y, et al. EVOLVE-1: phase 3 study of everolimus for advanced HCC that progressed during or after sorafenib. J Clin Oncol 2014:32(suppl 3). Abstract 172.